Deals In Depth: January 2017
Executive Summary
Servier signed a $1.7 billion immuno-oncology deal with Pieris; Johnson & Johnson paid $30 billion to acquire Actelion and its key pulmonary arterial hypertension assets. Device fundraising was significantly boosted by Verily's $800 million investment from Temasek.